Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients

@inproceedings{Rutten2016LossOS,
  title={Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients},
  author={Iris J.G. Rutten and David P J van Dijk and Roy F. P. M. Kruitwagen and Regina G.H. Beets‐Tan and Steven W. M. Olde Damink and Toon van Gorp},
  booktitle={Journal of cachexia, sarcopenia and muscle},
  year={2016}
}
BACKGROUND Malnutrition, weight loss, and muscle wasting (sarcopenia) are common among women with advanced ovarian cancer and have been associated with adverse clinical outcomes and survival. Our objective is to investigate overall survival (OS) related to changes in skeletal muscle (SM) for patients with advanced ovarian cancer treated with neoadjuvant chemotherapy and interval debulking. METHODS Ovarian cancer patients (n = 123) treated with neoadjuvant chemotherapy and interval debulking… CONTINUE READING